Evaluation of parking-related financial toxicity associated with cancer treatments in Western Canada

Balushi, Mustafa Al; Zhu, Michael X.; Yang, Fan; Nijjar, Yugmel; Hill, Jordan; Ghosh, Sunita

doi:10.1016/j.jmir.2022.11.006

Cited by 2 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This variation in travel and constraints results in a shift in patient accessibility to healthcare in the context of public health and care equity. This is an area of health service—out-of-pocket cost to patients and visitors—that has been investigated minimally outside of cancer care 1–7. Investigators have found that out-of-pocket costs including parking costs are one of many factors that prevent patients from visiting hospitals, even for cancer treatment.…”

Section: Introductionmentioning

confidence: 99%

“…This is an area of health service-out-of-pocket cost to patients and visitors-that has been investigated minimally outside of cancer care. [1][2][3][4][5][6][7] Investigators have found that out-of-pocket costs including parking costs are one of many factors that prevent patients from visiting hospitals, even for cancer treatment. While patients with other chronic illnesses are likely to also require multiple hospital outpatient clinic attendances, we have not found similar analyses on this topic that are generalisable across the larger patient population.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Estimating the cost of visiting hospital outpatient

Liyana Arachige,

Tse,

Zhang

et al. 2024

BMJ Neurol Open

View full text Add to dashboard Cite

ObjectivesThis study aims to investigate the cost incurred by people travelling to the neurology outpatient clinic of a large metropolitan hospital. As outpatients are a substantial portion of a hospital’s demographic, we aimed to understand the patient experience of various commuters.MethodsWe conducted an observational study collecting demographic details and travel information for how people attended the neurology clinic of Monash Medical Centre. Statistical analysis was performed using R. 165 participants were randomly selected and interviewed in-person. Data were collected via an anonymous questionnaire. The study was approved by the Monash Health Human Ethics Research Committee.Results155 responses were included in the analysis. Patients paid an average of $A16.64 to travel to Monash Medical Centre. Drivers paid on average $A16.70 and those taking public transport paid on average $A9.64, with the maximum cost overall being $A120.00. For patients driving to hospital, parking accounted for 60% of their travel costs. The average to Monash Medical centre was 20.82 km with the maximum being 190.88 km. Distance from hospital was correlated with a higher cost of travel (p<0.001, Spearman’s rank correlation coefficient=0.48). There was also an inverse association between distance from hospital and socioeconomic status (p<0.001, Spearman’s rank correlation coefficient=−0.26).ConclusionTravelling to hospital can be a costly endeavour. Driving is the most popular form of transport, but a large portion of the cost involved is hospital parking. Further research should be conducted at other tertiary centres with larger samples.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Estimating the cost of visiting hospital outpatient

Liyana Arachige,

Tse,

Zhang

et al. 2024

BMJ Neurol Open

View full text Add to dashboard Cite

show abstract

Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effort

Budhu,

Chukwueke,

Jackson

et al. 2023

Neuro-Oncology

View full text Add to dashboard Cite

Despite major strides in cancer research and therapy, these advances have not been equitable across race and ethnicity. Historically marginalized groups (HMG) are more likely to have inadequate preventive screening, increased delays in diagnosis, and poor representation in clinical trials. Notably, Black, Hispanic, and Indigenous people represent 30% of the population but only 9% of oncology clinical trial participants. As a result, HMGs lack equitable access to novel therapies which contradicts the principle of distributive justice; as enshrined in the Belmont report, which demands the equitable selection of subjects in research involving human subjects. The lack of clinical trial diversity also leads to low generalizability and potentially harmful medical practices. Specifically, patients with brain cancer face unique barriers to clinical trial enrollment and completion due to disease-specific neurologic and treatment induced conditions. Collectively, the intersection of these disease-specific conditions with social determinants of health fosters a lack of diversity in clinical trials. To ameliorate this disparity in neuro-oncology clinical trial participation, we present interventions focused on improving engagement of HMGs. Proposals range from inclusive trial design, decreasing barriers to care expanding trial eligibility, access to tumor profiling for personalized medical trials, setting reasonable metrics and goals for accrual, working with patient community stakeholders, diversifying the neuro-oncology workforce, and development of tools to overcome biases with options to incentivize equity. The diversification of participation amongst neuro-oncology clinical trials is imperative. Equitable access and inclusion of HMG patients with brain tumors will not only enhance research discoveries but will improve patient care.

show abstract

Evaluation of parking-related financial toxicity associated with cancer treatments in Western Canada

Cited by 2 publications

References 21 publications

Estimating the cost of visiting hospital outpatient

Estimating the cost of visiting hospital outpatient

Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effort

Contact Info

Product

Resources

About